- Home
- BCDA vs NLSP Comparison
BCDA vs NLSP Comparison
Compare BCDA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- NLSP
- Stock Information
- Founded
- BCDA N/A
- NLSP 2015
- Country
- BCDA United States
- NLSP Switzerland
- Employees
- BCDA N/A
- NLSP N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- NLSP Health Care
- Exchange
- BCDA Nasdaq
- NLSP Nasdaq
- Market Cap
- BCDA 7.9M
- NLSP 243.8M
- IPO Year
- BCDA N/A
- NLSP 2021
- Fundamental
- Price
- BCDA $2.68
- NLSP $4.55
- Analyst Decision
- BCDA Strong Buy
- NLSP
- Analyst Count
- BCDA 1
- NLSP 0
- Target Price
- BCDA $25.00
- NLSP N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- NLSP 33.1K
- Earning Date
- BCDA 11-06-2024
- NLSP 11-01-2024
- Dividend Yield
- BCDA N/A
- NLSP N/A
- EPS Growth
- BCDA N/A
- NLSP N/A
- EPS
- BCDA N/A
- NLSP N/A
- Revenue
- BCDA $428,000.00
- NLSP N/A
- Revenue This Year
- BCDA $6.92
- NLSP N/A
- Revenue Next Year
- BCDA N/A
- NLSP N/A
- P/E Ratio
- BCDA N/A
- NLSP N/A
- Revenue Growth
- BCDA 0.71
- NLSP N/A
- 52 Week Low
- BCDA $1.96
- NLSP $4.08
- 52 Week High
- BCDA $23.25
- NLSP $29.84
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- NLSP 40.59
- Support Level
- BCDA $2.39
- NLSP $4.38
- Resistance Level
- BCDA $2.90
- NLSP $5.64
- Average True Range (ATR)
- BCDA 0.18
- NLSP 0.47
- MACD
- BCDA -0.00
- NLSP 0.06
- Stochastic Oscillator
- BCDA 53.70
- NLSP 29.16
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.